Profund Advisors LLC increased its position in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 20.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,867 shares of the medical research company’s stock after purchasing an additional 6,067 shares during the quarter. Profund Advisors LLC’s holdings in EXACT Sciences were worth $3,317,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. First Business Financial Services Inc. lifted its holdings in shares of EXACT Sciences by 4.1% during the fourth quarter. First Business Financial Services Inc. now owns 3,020 shares of the medical research company’s stock valued at $279,000 after purchasing an additional 120 shares in the last quarter. Parallel Advisors LLC grew its position in shares of EXACT Sciences by 18.2% during the fourth quarter. Parallel Advisors LLC now owns 943 shares of the medical research company’s stock worth $87,000 after purchasing an additional 145 shares in the last quarter. Kovack Advisors Inc. grew its position in shares of EXACT Sciences by 6.0% during the fourth quarter. Kovack Advisors Inc. now owns 2,635 shares of the medical research company’s stock worth $244,000 after purchasing an additional 150 shares in the last quarter. American International Group Inc. grew its holdings in EXACT Sciences by 5.0% during the 4th quarter. American International Group Inc. now owns 3,281 shares of the medical research company’s stock valued at $303,000 after buying an additional 156 shares in the last quarter. Finally, Fulton Bank N.A. grew its holdings in EXACT Sciences by 6.9% during the 4th quarter. Fulton Bank N.A. now owns 2,812 shares of the medical research company’s stock valued at $260,000 after buying an additional 181 shares in the last quarter. 87.77% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:EXAS traded down $0.34 during trading hours on Thursday, reaching $60.89. 2,701,600 shares of the stock were exchanged, compared to its average volume of 2,765,412. The company has a market capitalization of $9.06 billion, a price-to-earnings ratio of -83.41 and a beta of 1.60. The company has a quick ratio of 2.09, a current ratio of 2.36 and a debt-to-equity ratio of 0.41. EXACT Sciences Co. has a twelve month low of $35.25 and a twelve month high of $123.99. The business has a 50-day moving average of $76.57 and a two-hundred day moving average of $88.27.

EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.91. The business had revenue of $295.58 million for the quarter, compared to analysts’ expectations of $294.39 million. EXACT Sciences had a negative return on equity of 18.78% and a negative net margin of 9.59%. On average, research analysts forecast that EXACT Sciences Co. will post -1.89 EPS for the current fiscal year.

In other EXACT Sciences news, insider Jacob A. Orville sold 1,153 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $100.68, for a total transaction of $116,084.04. Following the transaction, the insider now owns 3,648 shares of the company’s stock, valued at $367,280.64. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director James Edward Doyle sold 2,000 shares of the firm’s stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $77.54, for a total value of $155,080.00. Following the transaction, the director now directly owns 32,440 shares in the company, valued at approximately $2,515,397.60. The disclosure for this sale can be found here. Insiders sold 52,731 shares of company stock worth $4,462,531 in the last three months. 2.20% of the stock is currently owned by corporate insiders.

A number of equities research analysts recently issued reports on the company. Canaccord Genuity reissued a “buy” rating and set a $120.00 price target on shares of EXACT Sciences in a research note on Wednesday, February 12th. Citigroup assumed coverage on EXACT Sciences in a research note on Monday, January 6th. They set a “buy” rating and a $120.00 target price on the stock. ValuEngine raised EXACT Sciences from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. BidaskClub cut EXACT Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Finally, TheStreet cut EXACT Sciences from a “c-” rating to a “d+” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $122.43.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Featured Story: What is Compound Interest?

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).

Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.